WebMD Health News
Reviewed By Louise Chang, MD
In the clinical trials, COPD patients taking Symbicort had a greater improvement in their lung function, compared to patients using a placebo, formoterol, or budesonide.
It typically took five minutes for lung function to start to improve with Symbicort treatment, and Symbicort was generally well tolerated.
In one of the trials, which lasted for a year, potential lung infections other than pneumonia were more common among patients using Symbicort than among those using the placebo or formoterol. The most common side effects were colds, oral thrush, bronchitis, sinusitis, and viral infections of the upper respiratory tract.
SOURCES: News release, FDA. News release, AstraZeneca.
©2009 WebMD, LLC. All Rights Reserved.